VivoSeq
Oncology

Neoplasms

31

Pipeline Programs↗

20

Active Trials↗

15

Companies Involved↗

Neoplasms is a moderately active landscape with 31 programs across 15 companies. The most active players are Johnson & Johnson, GSK, Johnson & Johnson Enterprise Innovation Inc.. 5 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

27/100

Mech. Concentration

20/100

Completion Rate

60/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

7 programs

Phase 1GSK logo

GSK

4 programs

Phase 1J

Johnson & Johnson Enterprise Innovation Inc.

3 programs

Phase 1Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 1Incyte logo

Incyte

2 programs

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

74%

Small molecule

20 of 27 classified programs — the dominant modality here.

26%ALL OTHERSMonoclonal antibody726%

Small molecule leads; the ring shows all 27 classified programs, each share of the total. Modality classified for 85% of 33 pipeline programs.

Analysis

Trial Status

30

clinical trials

Recruiting11 · 37%
Completed6 · 20%
Active, not recruiting4 · 13%
Terminated3 · 10%
Not yet recruiting3 · 10%
Enrolling by invitation2 · 7%
Other1 · 3%

Clinical Trials

Trial Activity

30 trials

Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07382817·33 enrolled
A Phase 1b-2, Open-Label, Dose-Escalation, Expansion and Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of LRK-4189 Alone and in Combination With mFOLFOX6 or FOLFIRI in Patients With Solid Tumors
Recruiting·LLARKSPUR BIOSCIENCES, INC.·Preclinical·NCT07498725·120 enrolled
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Radiation Therapy
Recruiting·PProton Collaborative Group·N/A·NCT01255748·50,000 enrolled
Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT03435796·1,541 enrolled
Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT03366116·65 enrolled
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06150157·241 enrolled
Phase 1 Study of Intratumoral Administration of JNJ-1761981 ER, an Extended Release Chemotherapy, in Participants With Solid Tumors
Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT07525141·66 enrolled
Phase 1 Study of Intratumoral Administration of JNJ-87704916, an Oncolytic Virus, as Monotherapy and in Combination for Advanced Solid Tumors
Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT06311578·126 enrolled
A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06178614·200 enrolled
A Phase 1b/2, Open-Label, Dose-Finding and Proof of Concept Study of Nenocorilant in Combination With Anti-Programmed Cell Death/(Ligand) 1 in Patients With Advanced Solid Malignancies
Recruiting·CCorcept Therapeutics·Preclinical·NCT07276373·50 enrolled
A Phase 1, Open-Label Study to Evaluate the Safety, Biodistribution, Imaging Characteristics, and Radiation Dosimetry of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07258836·41 enrolled
An Open Label, Phase I Dose-finding and Expansion Study of BI 765179 as Monotherapy and in Combination With Ezabenlimab (BI 754091) in Patients With Advanced Solid Cancers, and BI 765179 in Combination With Pembrolizumab in First-line PD-L1-positive Metastatic or Incurable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Active, not recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT04958239·151 enrolled
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT04606381·158 enrolled
An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Active, not recruiting·Roche logoRoche·Phase 3·NCT05112965·49 enrolled
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
Active, not recruiting·GSK logoGSK·Phase 1·NCT05277051·152 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)